Description of Erlocip
* Brand Name : Erlocip
* Composition : Erlotinib hydrochloride
* Manufactured by : Cipla Ltd.
* Strength : 150 mg
* Dosage Form : Tablets
* Packing : Pack of 30 Tablets
Erlocip is a anticancer drug , manufactured by Cipla and it belongs to class of tyrosine kinase inhibitor,which prevent the growth of cancer cells and reduce the spreadness in the body. Erlocip tablet indicated for non-small cell lung cancer or pancreatic cancer which spread to all over the body. It has been given after other cancer drug used without achieve success. Erlocip contain Erlotinib as active ingredient. Erlocip is a prescription based drug, without prescription should not be issued.
Pharmacology of Erlocip
MECHANISM OF ACTION
Epidermal growth factor receptor (EGFR) is demonstrated on the surface of cell of both cancer and normal cells. Erlocip plays a role in tumor cell survival and perforation by some tumour cells wave through the receptor with irrespective of EGFR mutation status. By action of Epidermal growth factor receptor, Erlocip feasibly prevent the kinase thereby inhibits autophosphorylation of tyrosine excess attached with the receptor and interferes further downstream waving. Erlocip prevention of other tyrosine kinase receptors have not been fully established.
ABSORPTION: After oral administration, 60% absorbed by Erlocip and is bioavailability is subsequently increased by food (100%). Erlocip occurs peak plasma level about 4 hours after dosing.
DISTRIBUTION: Erlocip bounded to plasma albumin protein and alpha-1acid glycoprotein is approximately 93%.
METABOLISM: Erlocip primarily metabolized by CYP3A4 and to a lesser action by CYP1A2, and the extrahepatic isoform CYP1A1. Erlocip reach steady state plasma concentration about 7-8 days.
EXCRETION: In Erlocip150mg oral dose, 91% dose recovered,in which 83% in feces and 8% in urine and half life of 36.2 hours.
Indication of Erlocip
Erlocip is used for the first line therapy of patient who suffering from advanced non-Small cell lung cancer(NSCLC) without recover after four cycles.
Erlocip is indicated for the treatment of first line therapy with metastatic pancreatic cancer.
Dose & Dosage's of Erlocip
Metastatic non-small cell lung carcinoma:
Erlocip adult dose 150mg once daily in serious stage and reduce dose by slow down of 50mg when necessary.
Advanced, undetectable pancreatic carcinoma: Erlocip adult dose in first line therapy with gemcitabine is 100mg. when necessary it will reduce to 50mg.
CYP3A4 or CYP1A2 inhibitor patients: reduce dose in slow down of 50mg, when required.
Smokers: Erlocip Increased dose of 50mg at 2 week interval.
Erlocip should be administrated on an empty stomach(1hr before or 2 hr after meals). Erlocip is used by oral administration.
Side Effects of Erlocip
Erlocip has serious adverse reaction as follows:
Kidney failure; Myocardial Infarction; Bleeding in patient taking warfarin; Cerbrovascular accident; Gastrointestinal proliferation; Hepatotoxicity with or without hepatic impairment ; interstitial lung disease; ocular discomfort; Hemolytic anemia with thrombocytopenia; Exfoliative skin disorders.
Contraindication of Erlocip
The patient with severe hypersensitivity or to any substance of Erlocip is contraindicated by drug Erlocip
Drug Interaction of Erlocip
Reduce exposure of Erlocip tablet by interacting with potent CYP3A4 inhibitor and CYP3A4 inducers. Interaction with increased serum level of potent CYP1A2 inhibitors and CYP1A2 inducers causes altered elimination of Erlocip . Interaction with antacids and H2 receptors (increased PH) may affects the solubility of Erlocip and reduce bioavailability.
Precaution of Erlocip
If the patient has hepatic disease, lung or breathing difficulty (other than lung cancer), Erlocip should not be given without taking advice from doctors .Do not take , or products involving , unless recommended by the doctor. Patient must take Erlocip at equal time gap, if antacids are also being taken or any of its constituents, then intake is not adjustable. If the patient is pregnant or breast feeding the child then Erlocip drug should be avoided. Doctor consultation suggested for use of control of birth during therapy with Erlocip . Whether Erlocip passes into breast milk or not is not yet established.
Usage & Safety profile of Erlocip Pregnancy & Lactation
Based on aftereffects there is positive evidence of human fetal risk In pregnant women use of Erlocip may be gain acceptable against the risk means if the drug is used in a life-threatening situation are ineffective.
Storage of Erlocip
Erlocip should be store at 250C. Do not keep medicine near to the children accessible. Erlocip store at cool and dry place and store it in its own original container after usage of medicine. Keep away from spouse or other family members avoid accidentally change of medicine.